MCGRAW BENJAMIN F III 4

What Happened
Benjamin F. McGraw III, a director of Evommune, was granted a derivative award covering 15,673 shares on June 2, 2026. The grant was reported as having $0.00 per-share cost (an option/award rather than an open‑market purchase) and no immediate cash transaction occurred. This is an award/retention grant — not a sale — and typically reflects compensation rather than an immediate bullish or bearish trading signal.

Key Details

• Transaction date: 2026-06-02; Filing date: 2026-06-03 (timely filing). Transaction code: A (award/grant/other acquisition).
• Amount: 15,673 shares (derivative award) at $0.00 per share; total cash paid = $0.
• Shares owned after transaction: not specified in the Form 4 provided.
• Footnote: Vesting occurs at the earlier of (i) the first anniversary of the grant date or (ii) the issuer’s next annual meeting of stockholders, subject to the reporting person’s continuous service through the vesting date.
• No indication of exercise, sale, or tax‑withholding reported with this grant.

Context
This was a routine equity award to a company director (not an immediate exercise or sale). For retail investors, such grants are common as compensation/retention tools and do not by themselves signal an immediate change in insider sentiment.